Document is current

Article History

Accepted: 8 March 2023

First Online: 5 April 2023

Compliance with Ethical Standards

:

: Dr. LeBlanc’s work on palliative care in hematology is funded in part by a Scholar in Clinical Research grant from the Leukemia and Lymphoma Society.Dr. Leblanc has currently, or has recently been a consultant for/received honoraria from AbbVie, Agilix, Agios/Servier, Astellas, AstraZeneca, Beigene, BlueNote, BMS/Celgene, CareVive, Flatiron, Genentech, GSK, Lilly, Meter Health, Novartis, and Pfizer. He has served on recent advisory boards for AbbVie, Agios, and BMS. He has received honoraria from AbbVie, Agios, Astellas, BMS/Celgene, and Incyte for recent speaking engagements. He also has equity interest in Dosentrx and has received recent research funding from the American Cancer Society, AstraZeneca, BMS, Deverra Therapeutics, Duke University, Jazz Pharmaceuticals, the Leukemia and Lymphoma Society, the National Institute of Nursing Research/ National Institutes of Health, and Seattle Genetics.Dr. El-Jawahri received grants from National Institute of Health, Lymphoma and Leukemia Society, PCORI, Incyte, American Cancer Society, and Blue Note Therapeutics. Dr. El-Jawahri also received consulting fees from Incyte, GSK, AIMS Pathways, and Novartis.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Free to read: This content has been made available to all.